GSA Capital Partners LLP trimmed its stake in shares of American Vanguard Co. (NYSE:AVD – Free Report) by 32.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,976 shares of the basic materials company’s stock after selling 49,470 shares during the period. GSA Capital Partners LLP owned about 0.36% of American Vanguard worth $546,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Pullen Investment Management LLC grew its holdings in American Vanguard by 2.4% during the second quarter. Pullen Investment Management LLC now owns 70,089 shares of the basic materials company’s stock worth $603,000 after acquiring an additional 1,628 shares during the period. Gabelli Funds LLC grew its holdings in American Vanguard by 25.0% in the first quarter. Gabelli Funds LLC now owns 15,000 shares of the basic materials company’s stock valued at $194,000 after purchasing an additional 3,000 shares during the period. Point72 DIFC Ltd grew its holdings in American Vanguard by 195.7% in the second quarter. Point72 DIFC Ltd now owns 5,080 shares of the basic materials company’s stock valued at $44,000 after purchasing an additional 3,362 shares during the period. Kennedy Capital Management LLC grew its holdings in American Vanguard by 4.7% in the first quarter. Kennedy Capital Management LLC now owns 79,596 shares of the basic materials company’s stock valued at $1,031,000 after purchasing an additional 3,571 shares during the period. Finally, Gladius Capital Management LP acquired a new stake in American Vanguard in the second quarter valued at approximately $32,000. 79.04% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, StockNews.com raised American Vanguard from a “sell” rating to a “hold” rating in a report on Wednesday, September 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, American Vanguard has a consensus rating of “Moderate Buy” and a consensus price target of $16.67.
Insider Activity
In other news, Director Steven D. Macicek bought 12,000 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were acquired at an average price of $5.97 per share, for a total transaction of $71,640.00. Following the completion of the transaction, the director now directly owns 31,218 shares in the company, valued at $186,371.46. The trade was a 62.44 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Peter Eilers sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $5.80, for a total value of $29,000.00. Following the completion of the transaction, the insider now owns 42,905 shares in the company, valued at approximately $248,849. This trade represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have bought a total of 175,047 shares of company stock worth $1,009,845 over the last quarter. 10.10% of the stock is currently owned by corporate insiders.
American Vanguard Stock Up 3.2 %
Shares of AVD opened at $6.35 on Wednesday. The company has a current ratio of 1.89, a quick ratio of 0.79 and a debt-to-equity ratio of 0.55. American Vanguard Co. has a 12 month low of $4.95 and a 12 month high of $14.28. The stock’s 50 day moving average is $5.53 and its two-hundred day moving average is $7.26. The firm has a market cap of $182.67 million, a P/E ratio of -6.16 and a beta of 0.88.
American Vanguard Company Profile
American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally. It manufactures and formulates chemicals, including insecticides, fungicides, herbicides, soil health, plant nutrition, molluscicides, growth regulators, soil fumigants, and biorationals in liquid, powder, and granular forms for crops, turf and ornamental plants, and human and animal health protection.
Further Reading
- Five stocks we like better than American Vanguard
- How to Most Effectively Use the MarketBeat Earnings Screener
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Business Services Stocks Investing
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- What is a Special Dividend?
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for American Vanguard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Vanguard and related companies with MarketBeat.com's FREE daily email newsletter.